Compare ENS & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENS | GH |
|---|---|---|
| Founded | 1991 | 2011 |
| Country | United States | United States |
| Employees | N/A | 2021 |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4B | 13.2B |
| IPO Year | N/A | 2018 |
| Metric | ENS | GH |
|---|---|---|
| Price | $157.98 | $112.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 21 |
| Target Price | ★ $151.33 | $99.48 |
| AVG Volume (30 Days) | 428.0K | ★ 1.8M |
| Earning Date | 02-04-2026 | 02-19-2026 |
| Dividend Yield | ★ 0.68% | N/A |
| EPS Growth | ★ 21.73 | N/A |
| EPS | ★ 8.58 | N/A |
| Revenue | ★ $3,725,304,000.00 | $902,569,000.00 |
| Revenue This Year | $4.71 | $35.00 |
| Revenue Next Year | $2.75 | $26.80 |
| P/E Ratio | $18.05 | ★ N/A |
| Revenue Growth | 6.17 | ★ 30.38 |
| 52 Week Low | $76.57 | $33.75 |
| 52 Week High | $156.21 | $112.43 |
| Indicator | ENS | GH |
|---|---|---|
| Relative Strength Index (RSI) | 70.00 | 70.14 |
| Support Level | $146.66 | $97.31 |
| Resistance Level | $151.43 | $104.75 |
| Average True Range (ATR) | 4.02 | 3.83 |
| MACD | 0.28 | 0.26 |
| Stochastic Oscillator | 99.04 | 99.25 |
EnerSys provides stored energy solutions for industrial applications. It also manufactures and distributes energy systems solutions and motive power batteries, specialty batteries, battery chargers, power equipment, battery accessories, and outdoor equipment enclosure solutions to customers. Energy Systems that combine enclosures, power conversion, power distribution, and energy storage are used in the telecommunication and broadband, utility industries, uninterruptible power supplies, and numerous applications requiring stored energy solutions. Its segments include Energy Systems, Motive Power, and Specialty.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.